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303Abstracts
96,144 patients initiating sildenaﬁl switched to another PDE-5
agent (57% tadalaﬁl). Prior to switching, the majority of patients
(64%) had only one prescription for sildenaﬁl and only 4% of
those initiated on a lower dose titrated to the 100mg dose. Mean
time to switch from last sildenaﬁl dose was 67–77 days. After
switching, about 38% and 34% of tadalaﬁl and vardenaﬁl
patients reﬁlled therapy, respectively. Between 22% of tadalaﬁl
and 27% of vardenaﬁl patients switched back to sildenaﬁl.
CONCLUSIONS: The majority of patients who initiated silde-
naﬁl did not switch to a competitor. Among those who did, most
either switched back to sildenaﬁl or did not reﬁll treatment.
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OBJECTIVES: To examine the direct costs of erectile dysfunc-
tion (ED) in a managed care setting. METHODS: A naturalistic
and retrospective observational study was conducted with an ED
cohort (285,436) of men age 18 or older and enrolled in 51US
health plans that covered 28 million lives from 1999 through
2001. Both annual costs of ED care per patient with ED and
annual costs of ED care per user were measured for each cate-
gory of ED-related care and treatments. RESULTS: On average,
health plans spent $83.91, $95.41 and $119.26 on ED care 
for a patient with ED in 1999, 2000, and 2001 respectively. In
2001, an ED patient spent $44.22 on phosphodiesterase type 5
(PDE-5) inhibitor therapy, $14.56 on ED-related physicians’
evaluation and management, $10.13 on ED-related diagnosis
procedures, $10.08 on ED-related testosterone therapy, $2.70 on
intracavernosal injection, $1.49 on alprostadil pellet, $3.27 on
penile prosthesis implantation, $0.72 on vacuum erection device,
and $0.13 on ED-related vascular surgery (see Figure 1). Among
seven common ED treatments, PDE-5 inhibitor had the lowest
average annual costs per user of a treatment (see Figure 2). From
1999 through 2001, a health plan with 100,000 members might
spend $320,865 (2000 dollars) on ED care, about one tenth of
the costs forecasted by Tan ($3,204,792 in 1998 dollars)1. The
largest per member per month cost of ED treatment was for
PED-5 inhibitor ($0.48 in 2001), followed by testosterone
therapy ($0.11 in 2001). CONCLUSIONS: In 2001, ED imposed
a modest ﬁnancial burden on a health plan ($122,699 for a plan
with 100,000 members). Although the use of PDE-5 inhibitor
therapy had the lowest annual treatment costs per user ($121.7
in 2001), it constituted 37.08% of the annual ﬁnancial burden
of ED (2001), followed by testosterone therapy (8.45% or
$10,369).
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OBJECTIVES: The purpose of this study was to estimate the
health care cost savings in 2001 to the British Columbia Min-
istry of Health Services (MHS) as a result of the policy of autho-
rizing pharmacist provision of Emergency Contraception (EC)
without a physician visit. A secondary objective of this study was
to estimate whether, and at what price, a media campaign to
increase public awareness and EC utilization to prevent unin-
tended pregnancies in the province would be cost effective.
METHODS: A decision analytic model was developed to
compare the difference in incremental marginal costs and effects
between the MHS policy of pharmacist prescribing authority for
EC compared to the previous policy of no pharmacist prescrib-
ing authority for EC. A second model was developed to deter-
mine the costs and effects of increased EC utilization in British
Columbia. The possible outcomes were: pregnancy, no preg-
nancy, induced abortion, spontaneous abortion and ectopic 
pregnancy. Cost and event data were obtained from MHS. A
conception rate of 4.3% was used in both models. In the
expanded use model, we assumed both a 28% increase in aware-
ness and 10% increase in usage in the base case; these assump-
tions were varied in the sensitivity analyses. The analysis was
conducted from the MHS perspective for calendar year 2001.
Monte-Carlo simulations were conducted to determine conﬁ-
dence ranges for the results. RESULTS: The policy of pharma-
cist-initiated EC was estimated to have saved the MHS $480,985
(95% CR: $237,213, $1,084,489). It was estimated that
expanded EC use would save $1,610,678 (95% CR: $419,074,
$4,683,870). CONCLUSIONS: The results of this cost effec-
tiveness analysis indicates that the policy of pharmacist provi-
sion of EC is cost saving. A media campaign to increase EC
utilization costing less than $0.42 million would be cost neutral
or cost saving in the ﬁrst year.
PIH20
COST OF ILLNESS STUDY OF NAUSEA AND VOMITING OF
PREGNANCY IN CANADA
Piwko C1, Ungar WJ1, Einarson TR2, Koren G1
1The Hospital for Sick Children,Toronto, ON, Canada; 2University of
Toronto,Toronto, ON, Canada
OBJECTIVES: Nausea and vomiting of pregnancy (NVP) is the
most common medical condition in pregnancy affecting an 
estimated 80% (50%–90%) of all pregnant women. Even with
mild symptoms, NVP generates costs to society, patients and the
health care system, and reduces quality of life. However, its costs
are largely unknown. We estimated the total cost per woman-
week associated with the onset of NVP in Canada, stratiﬁed by
the self-reported severity (mild, moderate, severe) from the per-
spectives of society, Ministry of Health and Long Term Care
(MoH), and patients. METHODS: Data were collected from 
139 pregnant women, who called the Motherisk Program at 
the Hospital for Sick Children in Toronto. Motherisk is a tera-
tology information and counseling service for all questions
related to pregnancy. We collected the information about
resource utilization for direct costs (drugs, physicians, hospital-
izations) and indirect costs by telephone interviews. Costing 
was conducted with Ontario price lists and fee schedules. Indi-
rect costs were calculated using the human capital approach 
and included absences from work and/or usual activities as well
as reduced productivity at work. RESULTS: From the societal
perspective, the costs per woman-week were $124, $334 And
$610 for mild, moderate and severe NVP, respectively. From 
the MoH perspective, the costs were $4, $36, and $87, respec-
tively. From the patient perspective, costs per woman-week 
were $110, $253 and $375, respectively. Costs from all per-
spectives increased with increasing NVP severity. Lost produc-
tivity constituted the largest cost component. CONCLUSIONS:
NVP in Canada is associated with substantial costs to patients,
